Cargando…

Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?

Recent advances in immunology enabled the characterization of several signal transmitting pathways responsible for proper cytokine and chemokine signaling. Among them, Janus kinases (JAKs) are essential components of receptor activation systems. The discovery of JAK kinases enabled the synthesis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotyla, Przemysław J., Engelmann, Małgorzata, Giemza-Stokłosa, Joanna, Wnuk, Bartosz, Islam, Md Asiful
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957632/ https://www.ncbi.nlm.nih.gov/pubmed/33671049 http://dx.doi.org/10.3390/ijms22052449

Ejemplares similares

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus
por: Kotyla, Przemysław, et al.
Publicado: (2022)

Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
por: Kotyla, Przemyslaw J.
Publicado: (2018)

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment
por: Gumkowska-Sroka, Olga, et al.
Publicado: (2019)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review
por: Islam, Md Asiful, et al.
Publicado: (2020)

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
por: Wen, Ji, et al.
Publicado: (2021)

Editorial: Autoimmunity and cardiovascular diseases
por: Khandker, Shahad Saif, et al.
Publicado: (2023)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors
por: Troncone, Edoardo, et al.
Publicado: (2020)

Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome
por: Volpi, Stefano, et al.
Publicado: (2019)

Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
por: Mori, Shunsuke, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
por: Zhang, Juqi, et al.
Publicado: (2023)

JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations
por: Menshawey, Rahma, et al.
Publicado: (2020)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
por: Setyawan, Juliana, et al.
Publicado: (2021)

Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
por: Rajasimhan, Suraj, et al.
Publicado: (2021)

Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
por: Papierzewska, Małgorzata, et al.
Publicado: (2023)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
por: Abdou, Asmaa Gaber, et al.
Publicado: (2018)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis
por: Schäfer, Arne, et al.
Publicado: (2022)

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases
por: Felis-Giemza, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26son2s6qd8tbevgerjjgpj4s4